

BIOTECHNOLOGY FUND

	SHARES	VALUE
COMMON STOCKS - 99.6%		
BIOTECHNOLOGY - 73.0%		
Amgen, Inc.	19,065	\$ 6,903,818
Gilead Sciences, Inc.	48,654	6,146,946
Vertex Pharmaceuticals, Inc.*	11,897	5,909,597
Regeneron Pharmaceuticals, Inc.	6,432	4,010,609
Revolution Medicines, Inc.*	18,109	3,391,453
Alnylam Pharmaceuticals, Inc.*	10,721	3,227,343
BeOne Medicines Ltd. ADR*	10,427	2,971,382
Moderna, Inc.*	41,976	2,939,579
Biogen, Inc.*	13,465	2,909,248
Royalty Pharma plc — Class A	49,095	2,752,757
Illumina, Inc.*	15,058	2,647,648
Insmed, Inc.*	22,998	2,452,047
United Therapeutics Corp.*	4,350	2,356,960
Roivant Sciences Ltd.*	64,115	2,269,030
Incyte Corp.*	19,518	2,212,560
Argenx SE ADR*	2,181	2,023,466
Bridgebio Pharma, Inc.*.(a)	25,399	1,891,717
Ionis Pharmaceuticals, Inc.*	23,328	1,849,677
Cytokinetics, Inc.*.(a)	21,687	1,847,516
Exelixis, Inc.*	33,461	1,820,613
Arrowhead Pharmaceuticals, Inc.*	20,951	1,707,716
BioMarin Pharmaceutical, Inc.*	29,626	1,695,200
Halozyne Therapeutics, Inc.*	20,474	1,602,500
BioNTech SE ADR*	17,055	1,586,968
CRISPR Therapeutics AG*	29,038	1,583,732
TG Therapeutics, Inc.*.(a)	27,004	1,483,600
Apogee Therapeutics, Inc.*	10,512	1,395,258
Cogent Biosciences, Inc.*	35,458	1,372,225
PTC Therapeutics, Inc.*	16,516	1,347,210
Scholar Rock Holding Corp.*	24,468	1,345,740
Nuvalent, Inc. — Class A*	10,892	1,345,162
Axsome Therapeutics, Inc.*	5,367	1,313,681
CG oncology, Inc.*	18,440	1,310,162
Krystal Biotech, Inc.*.(a)	3,406	1,265,908
Viking Therapeutics, Inc.*.(a)	31,452	1,226,943
Traverse Therapeutics, Inc.*	21,589	1,226,471
Veracyte, Inc.*	20,449	1,200,970
Liquidia Corp.*.(a)	14,813	1,181,040
Kymera Therapeutics, Inc.*	9,937	1,139,476
Ultragenyx Pharmaceutical, Inc.*	31,574	1,054,256
Beam Therapeutics, Inc.*	29,626	1,016,764
ImmunifyBio, Inc.*.(a)	115,501	1,011,211
Praxis Precision Medicines, Inc.*	2,953	988,635
ACADIA Pharmaceuticals, Inc.*	38,546	975,214
Intellia Therapeutics, Inc.*	52,464	887,691
Arcutis Biotherapeutics, Inc.*	32,799	859,990
Reursion Pharmaceuticals, Inc. — Class A*(a)	203,986	748,629
Sarepta Therapeutics, Inc.*.(a)	41,327	742,646
Summit Therapeutics, Inc.*	49,916	727,276
Legend Biotech Corp. ADR*	23,843	688,586
ADMA Biologics, Inc.*	82,224	688,215

	SHARES	VALUE
COMMON STOCKS - 99.6% (continued)		
BIOTECHNOLOGY - 73.0% (continued)		
Celcuity, Inc.*	5,918	\$ 619,141
Total Biotechnology		<u>99,872,182</u>
PHARMACEUTICALS - 20.4%		
AbbVie, Inc.	44,415	11,176,591
Viatis, Inc.	133,745	2,123,871
Neurocrine Biosciences, Inc.*	12,363	2,083,598
Jazz Pharmaceuticals plc*	8,037	1,936,676
Alkermes plc*	34,306	1,797,463
AstraZeneca plc	8,846	1,677,378
Vaxcyte, Inc.*	27,188	1,580,438
Protagonist Therapeutics, Inc.*	9,900	1,213,542
Ascendis Pharma A/S*	4,546	1,212,509
Madrigal Pharmaceuticals, Inc.*.(a)	2,022	1,085,713
Mirum Pharmaceuticals, Inc.*	8,626	1,009,846
Rhythm Pharmaceuticals, Inc.*	8,809	978,063
Total Pharmaceuticals		<u>27,875,688</u>
HEALTHCARE-PRODUCTS - 5.2%		
Natera, Inc.*	10,672	2,896,914
Guardant Health, Inc.*	15,671	2,351,120
Twist Bioscience Corp.*	13,098	1,347,522
GRAIL, Inc.*	7,633	521,105
Total Healthcare-Products		<u>7,116,661</u>
HEALTHCARE-SERVICES - 1.0%		
Medpace Holdings, Inc.*	2,659	1,408,180
Total Common Stocks (Cost \$67,169,972)		<u>136,272,711</u>
RIGHTS - 0.0%		
BIOTECHNOLOGY - 0.0%		
Akero Therapeutics, Inc.(b)	17,387	2
CONSUMER, NON-CYCLICAL - 0.0%		
Sanofi S.A. Expiring 06/30/32*(b)	8,866	1
Total Rights (Cost \$0)		<u>3</u>
SECURITIES LENDING COLLATERAL(c) - 0.6%		
MONEY MARKET FUNDS - 0.6%		
BNY Dreyfus Treasury Obligations Cash Management Fund — Institutional Shares, 3.52%(d)	810,750	810,750
Total Securities Lending Collateral (Cost \$810,750)		<u>810,750</u>
	FACE	AMOUNT
REPURCHASE AGREEMENTS(e) - 0.6%		
J.P. Morgan Securities LLC issued 06/30/26 at 3.64% due 07/01/26	\$407,611	407,611

BIOTECHNOLOGY FUND

	FACE AMOUNT	VALUE
REPURCHASE AGREEMENTS^(e) - 0.6% (continued)		
Bank of America Securities, Inc. issued 06/30/26 at 3.63% due 07/01/26	\$407,591	\$ 407,591
Total Repurchase Agreements (Cost \$815,202)		815,202
Total Investments - 100.8% (Cost \$68,795,924)	\$	137,898,666
Other Assets & Liabilities, net - 0.0%		(1,118,663)
Total Net Assets - 100.0%	\$	136,780,003

* Non-income producing security.

^(a) All or a portion of this security is on loan at June 30, 2026 .

^(b) Value determined based on Level 3 inputs .

^(c) A copy of each underlying unaffiliated fund's financial statements is available at the SEC's website at www.sec.gov.

^(d) Rate indicated is the 7-day yield as of June 30, 2026.

^(e) Repurchase Agreements .

ADR — American Depositary Receipt

LLC — Limited Liability Company

plc — Public Limited Company